Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Change in Accured Expenses (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Change in Accured Expenses readings, the most recent being $971000.0 for Q4 2024.

  • On a quarterly basis, Change in Accured Expenses rose 127.4% to $971000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $790000.0, a 38.09% decrease, with the full-year FY2025 number at -$2.5 million, down 417.09% from a year prior.
  • Change in Accured Expenses hit $971000.0 in Q4 2024 for Unicycive Therapeutics, up from -$631000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.0 million in Q3 2022 to a low of -$641000.0 in Q4 2022.
  • Median Change in Accured Expenses over the past 3 years was -$23000.0 (2022), compared with a mean of $277750.0.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 904.17% in 2023 and later soared 525.91% in 2024.
  • Unicycive Therapeutics' Change in Accured Expenses stood at -$641000.0 in 2022, then soared by 166.61% to $427000.0 in 2023, then soared by 127.4% to $971000.0 in 2024.
  • The last three reported values for Change in Accured Expenses were $971000.0 (Q4 2024), -$631000.0 (Q3 2024), and -$372000.0 (Q2 2024) per Business Quant data.